Posted by Michael Wonder on 07 Jul 2024
FDA approves Genentech’s Vabysmo pre-filled syringe for three leading causes of vision loss
4 July 2024 - Vabysmo PFS is the first and only syringe pre-filled with an FDA approved bi-specific antibody to treat retinal conditions that can cause blindness.
Genentech announced today the US FDA has approved the Vabysmo (faricimab-svoa) 6.0 mg single-dose pre-filled syringe for use in the treatment of wet, or neovascular, age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion.
